证券代码：603658 证券简称：安图生物 公告编号：2024-085 郑州安图生物工程股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2024 年 11 月 25 日(星期一) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 18 日(星期一) 至 11 月 22 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 autobio@autobio.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 ...

Investment Rating - The report maintains a "Buy" rating for the company Antu Biology (603658) [2][6] Core Views - Despite external environmental pressures, the company's revenue has shown steady growth, and there are expectations for a performance turning point [2][4] - The company reported a revenue of 3.38 billion yuan in Q3 2024, reflecting a year-on-year growth of 3.38%, while the net profit for the same period was 337 million yuan, a decrease of 5.18% [3][4] Financial Performance Summary - For the first three quarters of 2024, the company achieved a total revenue of 3.38 billion yuan, a year-on-year increase of 4.24%, and a net profit of 956 million yuan, up 6.13% [3] - The operating cash flow for the first three quarters was 949 million yuan, showing a slight decline of 0.23% year-on-year [3] - The comprehensive gross margin for the first three quarters improved by 1.27 percentage points to 65.86%, while the overall net profit margin increased by 0.45 percentage points to 28.68% [5] Revenue and Profit Forecast - The company is expected to generate revenues of 4.666 billion yuan, 5.412 billion yuan, and 6.215 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 5%, 16%, and 15% [6][8] - The forecasted net profits for the same years are 1.325 billion yuan, 1.623 billion yuan, and 1.946 billion yuan, with growth rates of 9%, 22%, and 20% respectively [6][8] Market Position and Future Outlook - The report indicates that the company is likely to maintain stable growth, supported by a favorable installation trend of its product lines and high-speed chemiluminescence analyzers, which are expected to contribute significantly to reagent sales in the long term [4][5] - The anticipated implementation of inter-provincial alliance procurement for IVD reagents starting in September 2024 is expected to further boost sales volume [4]

Group 1: Performance Impact and Market Trends - The impact of the collection of infectious disease samples starting in September is expected to lower prices for involved projects but will lead to a continuous increase in sales volume, resulting in a positive long-term effect on the company [1] - The company anticipates a good installation trend for high-speed chemiluminescence instruments and production lines in the current macro environment [1] - The biochemistry collection in Jiangxi is gradually being implemented, which will have a certain impact on the company's biochemistry business, but the increase in production line installations is expected to improve the situation [2] Group 2: Future Business Outlook - The company sees single random and on-demand molecular diagnostic products as the future choice for hospitals, with an expectation of gradual acceleration in molecular business as more projects receive approval [2] - The development of regional testing centers is viewed as a current trend that is expected to be fully implemented in the future [2] - Prices for products in regions not participating in the collection are expected to gradually approach those in participating areas as the collection is fully implemented [2] Group 3: Financial Metrics and Projections - The company does not foresee significant short-term reductions in the sales expense ratio, but a decrease is expected in the future [2] - Future growth prospects are promising in regions such as Asia-Pacific, Latin America, and the Middle East and Africa [2] - The profit margin for overseas sales of luminescent projects is lower than that of domestic sales, but it is expected to rise with increased scale [2] Group 4: Inventory and Cost Management - The increase in inventory is primarily due to the company reducing production batches of certain products, leading to a noticeable rise in inventory levels [3] - The expected gross profit margin for magnetic microparticle luminescence is anticipated to decline as the collection progresses [3] - The company's agency business currently accounts for less than 20% of total business, and this proportion is not expected to increase in the future [2]

Investment Rating - The report maintains an "Accumulate" investment rating for the company [1] Core Views - Antu Bio, established in 1998, is a leading player in the domestic IVD segment, focusing on the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments [1] - The company reported a revenue of 3.38 billion yuan for the first three quarters of 2024, representing a year-on-year growth of 4.24%, while the net profit attributable to shareholders was 956 million yuan, up 6.13% year-on-year [1] - The gross margin for the first three quarters of 2024 was 65.86%, an increase of 1.27 percentage points compared to the same period last year [1] - The report projects earnings per share (EPS) of 2.59 yuan, 2.81 yuan, and 3.55 yuan for 2024, 2025, and 2026 respectively, with corresponding dynamic price-to-earnings ratios of 17.63, 16.27, and 12.84 based on the closing price of 45.65 yuan on November 4 [1] Summary by Relevant Sections Financial Performance - For Q3 2024, the company achieved a revenue of 1.173 billion yuan, a year-on-year increase of 3.38%, but the net profit decreased by 5.18% to 337 million yuan [1] - The sales expense ratio decreased by 0.38 percentage points to 16.32%, while the management expense ratio fell by 0.24 percentage points to 4.38% [1] Earnings Forecast - The report maintains the earnings forecast unchanged, expecting EPS of 2.59 yuan for 2024, 2.81 yuan for 2025, and 3.55 yuan for 2026 [1][3] - The projected revenue growth rates for the upcoming years are 12.68% for 2024, 11.74% for 2025, and 17.64% for 2026 [3][8] Valuation Metrics - The dynamic P/E ratios for the next three years are projected at 17.63 for 2024, 16.27 for 2025, and 12.84 for 2026 [1][3] - The report indicates a market capitalization of 26.523 billion yuan and a price-to-book ratio of 3.16 [1][8]

证券代码：603658 证券简称：安图生物 公告编号：2024-084 郑州安图生物工程股份有限公司 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间应当在每个月的前 3 个交易日内 公告截至上月末的回购进展情况，现将公司回购股份的进展情况公告如下： 2024 年 10 月，公司通过集中竞价交易方式已累计回购股份 282,860 股，成交 的最高价为 50.90 元/股、最低价为 44.03 元/股，已支付的总金额为 13,542,926.96 元（不含交易费用）。 截至2024年10月31日，公司通过集中竞价交易方式已累计回购股份9,174,352 股，占公司总股本的比例为 1.58%，成交的最高价为 59.99 元/股、最低价为 37.91 元/股，已支付的总金额为 427,735,574.17 元（不含交易费用）。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][10]. Core Views - The company's Q3 performance slightly underperformed expectations due to a tightening hospital environment and industry pressure on volume and price. However, the core chemiluminescence reagent business continues to achieve stable growth, and the product line is being further enriched, indicating a promising outlook for steady growth [2][10]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved revenue of 3.38 billion yuan, a year-on-year increase of 4.24%. The net profit attributable to shareholders was 956 million yuan, up 6.13%, while the net profit excluding non-recurring items was 931 million yuan, an increase of 6.69%. In Q3 alone, revenue was 1.173 billion yuan, a 3.38% increase, but net profit decreased by 5.18% to 337 million yuan due to increased management and R&D expenses, reduced investment income, and increased credit impairment losses [10][11]. - The gross margin for Q1-3 2024 was 65.86%, up 1.27 percentage points, with net profit margin at 28.29%, an increase of 0.50 percentage points [10]. Business Outlook - The company’s chemiluminescence business is expected to grow steadily despite industry challenges such as policy enforcement and price reductions. The company is anticipated to accelerate import substitution and increase market share as a leading player in the industry [10][11]. - The product line has been further enriched with multiple new chemiluminescence reagent registrations, enhancing overall competitiveness. The company has also launched a smart construction plan for regional medical testing centers, covering various testing fields and offering nearly 800 testing items [10][11]. Valuation and Target Price - The target price has been raised to 56.00 yuan, based on a 25x PE ratio for 2024, reflecting adjustments in EPS forecasts to 2.24/2.59/2.98 yuan for 2024-2026 [10][11].

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 58 yuan [1]. Core Insights - The company reported a revenue of 9.56 billion yuan for the first three quarters of 2024, reflecting a year-on-year increase of 6.13%. However, the net profit attributable to shareholders decreased by 5.18% to 3.37 billion yuan [1]. - The overall revenue growth remains stable despite short-term profit pressure due to increased expenses and credit impairment losses. The company has made adjustments in response to policy changes, which are expected to gradually improve performance [1]. - The gross profit margin for Q3 2024 was 66.80%, showing a slight increase of 0.45 percentage points year-on-year [1]. Financial Performance Summary - For Q3 2024, the company achieved a revenue of 3.32 billion yuan, with a net profit of 1.17 billion yuan, indicating a decline of 3.99% compared to the previous year [1]. - The company’s R&D expenses continue to be high, with a management expense ratio of 15.18%, up by 1.90 percentage points [1]. - The projected net profits for 2024, 2025, and 2026 are estimated at 1.34 billion yuan, 1.62 billion yuan, and 1.92 billion yuan respectively, with corresponding P/E ratios of 19, 16, and 14 times [1][3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its long-term development [5]. Core Views - The company experienced pressure on profit margins in Q3 2024, with revenue of 1.173 billion yuan, a year-on-year increase of 3.38%, while net profit attributable to shareholders decreased by 5.18% to 337 million yuan [3][5]. - The company continues to invest heavily in research and development, with R&D expenses reaching 178 million yuan in Q3 2024, a year-on-year increase of 18.18%, accounting for 15.18% of revenue [1][5]. - The company has made significant progress in international patents and certifications, including a new strategic partnership in the microbiological testing market [2]. Summary by Sections Financial Performance - In Q3 2024, the company achieved revenue of 1.173 billion yuan, up 3.38% year-on-year, while net profit attributable to shareholders was 337 million yuan, down 5.18% year-on-year [3][5]. - The gross profit margin improved by 0.45 percentage points to 66.8% in Q3 2024 [1]. Research and Development - The company invested 178 million yuan in R&D in Q3 2024, representing an 18.18% increase year-on-year and 15.18% of total revenue [1][5]. - The company received 24 medical device registration certificates in Q3 2024, including a series of self-antibody testing products developed over four years [1]. Strategic Developments - The company received an international invention patent for its fully automated microbiological identification and drug sensitivity analysis system in Q3 2024 [2]. - A strategic cooperation was established with a Japanese company to leverage strengths in the in vitro diagnostic field [2].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [5]. Core Insights - The company, Antu Bio (603658), reported a revenue of 3.38 billion yuan for Q3 2024, reflecting a year-over-year increase of 3.38%, while the net profit for the same period was 337 million yuan, showing a year-over-year decrease of 5.18% [3][4]. - For the first three quarters of 2024, the company achieved a total revenue of 3.38 billion yuan, up 4.24% year-over-year, and a net profit of 956 million yuan, up 6.13% year-over-year [3][4]. - The company's gross profit margin for Q3 2024 was 66.80%, an increase of 0.45 percentage points year-over-year, while the net profit margin decreased by 2.54 percentage points to 29.20% [4]. - The controlling shareholder has increased their stake in the company, and the company has initiated a share buyback program, indicating confidence in the company's future [4]. Financial Summary - The company expects revenues of 4.88 billion yuan, 5.46 billion yuan, and 6.34 billion yuan for 2024, 2025, and 2026 respectively, with corresponding net profits of 1.42 billion yuan, 1.59 billion yuan, and 1.86 billion yuan [4][8]. - The projected P/E ratios for the next three years are 18.89X, 16.91X, and 14.42X [4][8]. - The company has a total market capitalization of approximately 26.81 billion yuan [4].

费用中其实增加了就是有873万元那么这个注册费其实光国际注册有1000万出头这样的一个费用这里边可能就是有时候这是也是为长期的一个投资吧就是注册方面还有其他的当然是研发费是正常的一个增长管理费用除了就是说浙洲水电也有些是一次性的一些投资包括比如说就是说 花费包括像比如国际仲裁啊 原来这一块这些费用的也是会导致一些上升关于这个财务报表的情况我就基本上介绍到这里谢谢大家好的 我再把 我们那个数据筛分的情况再跟大家简单说一下这个可能很多人已经看到了三季报 记得就是三季度安图的那个磁规律发光是7点 消耗是7.15亿 增长是8%微空板试剂是230万这个下降50%媒类免疫试剂是1175万这个下降增长的微增长吧微生物检测试剂是9186万这增长3.8%核酸检测试剂是698万自产仪器是7850万这增长是15%这是自产仪器 代理的佳能生化业务是3773万下滑21.7%代理的酒莲碱1950万下滑59.5%其他代理产品是8715万增长16.6%北京安图生化试剂5200万下滑10.7% 其他资产品是5457万增长9.7%合作供电业务这其中合作供电业务下滑10%2023年前三季度2024年前三季度在收入方面磁威力发光是1916亿增长8. ...